J&J Zarnestra Efficacy Rate Likely To Be Focus Of Oncology Cmte. Review

FDA finds lower rate of complete responses in acute myeloid leukemia patients compared to Johnson & Johnson's analysis. Zarnestra (tipifarnib) oral dosing and low side-effect profile compared to standard chemotherapy may prove positive in the committee's evaluation.